What is the significance of the TAXUS™ Express²™ paclitaxel-eluting coronary stent system?

The TAXUS™ Express²™ paclitaxel-eluting coronary stent system is a medical device designed to release a drug (paclitaxel) at the site of a narrowed coronary artery. This drug is intended to prevent the re-narrowing of the artery (restenosis) after it has been opened with a procedure like angioplasty, thereby improving patient outcomes.

What does FDA approval mean for Boston Scientific?

FDA approval is a critical step that grants Boston Scientific the legal authorization to market and sell the TAXUS stent in the United States. It validates the device's safety and effectiveness based on clinical trial data, and it opens up a significant commercial opportunity for the company in the lucrative cardiovascular market.

How might this approval impact Boston Scientific's financials?

The commercial launch of the TAXUS stent is expected to be a key driver of future revenue growth for Boston Scientific. The success of this product in the market could lead to increased sales, improved market share, and enhanced profitability, positively impacting the company's financial performance and investor returns.

When was this approval officially announced?

The approval was announced by Boston Scientific via a press release issued on March 4, 2004. The company then filed this information on an 8-K Current Report with the SEC on March 9, 2004.

BSX 8-K SEC Disclosure

Summary

Boston Scientific Corporation (BSX) announced a significant regulatory milestone on March 4, 2004, with the United States Food and Drug Administration (FDA) granting approval to market its TAXUS™ Express²™ paclitaxel-eluting coronary stent system in the U.S. This approval represents a crucial step for the company, potentially opening up a substantial new revenue stream and strengthening its competitive position in the cardiovascular device market. The TAXUS stent is designed to release a drug to prevent re-narrowing of coronary arteries after angioplasty. The FDA approval is a critical validation of the product's safety and efficacy, paving the way for commercialization and sales. Investors will be closely watching the market reception and adoption of this new technology, which could significantly impact the company's future financial performance and stock valuation.

Key Highlights

1Boston Scientific received FDA approval for its TAXUS™ Express²™ paclitaxel-eluting coronary stent system in the United States.
2The approval allows the company to market and sell the TAXUS stent domestically.
3This signifies a major regulatory hurdle cleared for a key product in the cardiovascular segment.
4The TAXUS stent is designed for the treatment of coronary artery disease.
5The press release announcing this approval was issued on March 4, 2004.
6This event is reported on an 8-K filing dated March 9, 2004.

BOSTON SCIENTIFIC CORP 8-K Report (Mar 9, 2004)

Summary

Key Highlights

Frequently Asked Questions